Seragon Pharmaceuticals Inc.
Blocking and depleting receptors in estrogen-dependent tumors
This article was originally published in Start Up
Executive Summary
Seragon Pharmaceuticals Inc. spun out of Aragon Pharmaceuticals just days before J&J acquired it in 2013. Like Aragon, Seragon's mission is to develop orally active selective estrogen receptor degraders (SERDs) as treatments for cancers fueled by estrogen.
You may also be interested in...
Deal Watch: Genentech Pays Big For Seragon’s Early Assets
Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.
Strategic Spin-Outs: Biotechs Structure Their Progeny For Success
Placing assets in new companies is a growing trend for biotech start-ups; freed to evolve differently, spin-outs are structured to increase exit options and maximize investor returns. We profile Envisia Therapeutics, F-star Alpha, Onkaido Therapeutics, Seragon Pharmaceuticals, and True North Therapeutics.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.